Ossiam purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 195 shares of the company’s stock, valued at approximately $54,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Fundsmith LLP boosted its holdings in IDEXX Laboratories by 0.8% during the 1st quarter. Fundsmith LLP now owns 4,467,341 shares of the company’s stock worth $998,897,000 after acquiring an additional 35,049 shares during the last quarter. Blair William & Co. IL boosted its holdings in IDEXX Laboratories by 0.7% during the 1st quarter. Blair William & Co. IL now owns 1,582,222 shares of the company’s stock worth $353,785,000 after acquiring an additional 10,586 shares during the last quarter. American Century Companies Inc. boosted its holdings in IDEXX Laboratories by 111.2% during the 1st quarter. American Century Companies Inc. now owns 1,483,074 shares of the company’s stock worth $331,615,000 after acquiring an additional 780,846 shares during the last quarter. Geode Capital Management LLC boosted its holdings in IDEXX Laboratories by 7.6% during the 4th quarter. Geode Capital Management LLC now owns 1,162,909 shares of the company’s stock worth $215,959,000 after acquiring an additional 81,641 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in IDEXX Laboratories by 1.5% during the 2nd quarter. Northern Trust Corp now owns 1,079,474 shares of the company’s stock worth $297,211,000 after acquiring an additional 16,299 shares during the last quarter. 87.04% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:IDXX traded down $5.58 during midday trading on Friday, reaching $265.47. The company had a trading volume of 343,980 shares, compared to its average volume of 366,257. The company’s 50 day moving average price is $278.73 and its 200 day moving average price is $253.27. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 4.49. The stock has a market cap of $22.85 billion, a P/E ratio of 62.32 and a beta of 0.85. IDEXX Laboratories, Inc. has a 52-week low of $176.11 and a 52-week high of $292.17.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Thursday, August 1st. The company reported $1.43 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.37 by $0.06. The company had revenue of $620.10 million for the quarter, compared to the consensus estimate of $627.10 million. IDEXX Laboratories had a net margin of 17.78% and a return on equity of 765.45%. The firm’s quarterly revenue was up 6.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.23 EPS. Research analysts forecast that IDEXX Laboratories, Inc. will post 4.86 EPS for the current fiscal year.

A number of equities analysts have issued reports on IDXX shares. Stifel Nicolaus lifted their price objective on shares of IDEXX Laboratories from $255.00 to $295.00 and gave the stock a “buy” rating in a report on Monday, July 22nd. Goldman Sachs Group started coverage on shares of IDEXX Laboratories in a report on Monday, September 9th. They set a “neutral” rating and a $277.00 price objective on the stock. BidaskClub downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Guggenheim started coverage on shares of IDEXX Laboratories in a report on Thursday, May 23rd. They set a “buy” rating and a $276.00 price objective on the stock. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $285.00 price objective on shares of IDEXX Laboratories in a report on Friday, August 2nd. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $285.29.

In related news, Chairman Jonathan W. Ayers sold 20,000 shares of the business’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.26, for a total value of $5,245,200.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Sophie V. Vandebroek sold 9,044 shares of the business’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $263.86, for a total transaction of $2,386,349.84. Following the completion of the transaction, the director now directly owns 12,116 shares in the company, valued at $3,196,927.76. The disclosure for this sale can be found here. Insiders sold a total of 73,305 shares of company stock worth $19,402,442 over the last three months. 2.70% of the stock is owned by insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Featured Story: Why is the ex-dividend date different from the record date?

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.